

United States Department of Agriculture  
Center for Veterinary Biologics  
Testing Protocol

SAM 321

Supplemental Assay Method for Quantitating the GP70  
Antigen of Feline Leukemia Virus in Veterinary Vaccines

Date: June 6, 2005 Approved, Pending  
Standard Requirement

Number: VIRSAM0321.02

Supersedes: MVSAM0321.01, Dated December 22, 1999

Standard Requirement:

Contact: Alethea M Fry, (515) 663-7460  
Sandra K. Conrad, (515) 663-7659

Approvals:

/s/Donna M. Gatewood Date: 09Jun05  
Donna M. Gatewood, Section Leader  
Virology Section

/s/Byron E. Rippke Date: 13Jun05  
Byron E. Rippke, Director  
Policy, Evaluation, and Licensing  
Center for Veterinary Biologics

/s/Rebecca L.W. Hyde Date: 13Jun05  
Rebecca L.W. Hyde, Section Leader  
Quality Assurance  
Center for Veterinary Biologics

United States Department of Agriculture  
Animal and Plant Health Inspection Service  
P. O. Box 844  
Ames, IA 50010

Mention of trademark or proprietary product does not constitute a guarantee or warranty of the product by USDA and does not imply its approval to the exclusion of other products that may be suitable.

Supplemental Assay Method for Quantitating the GP70 Antigen of Feline Leukemia  
in Virus Veterinary Vaccines

Table of Contents

1. Introduction
2. Materials
  - 2.1 Equipment/instrumentation
  - 2.2 Reagents/supplies
3. Preparation for the test
  - 3.1 Personnel qualifications/training
  - 3.2 Preparation of equipment/instrumentation
  - 3.3 Preparation of reagents/control procedures
  - 3.4 Preparation of the sample
4. Performance of the test
5. Interpretation of the test results
6. Report of test results
7. References
8. Summary of revisions
9. Appendix

Supplemental Assay Method for Quantitating the GP70 Antigen of Feline Leukemia  
in Virus Veterinary Vaccines

## 1. Introduction

This Supplemental Assay Method (SAM) describes the enzyme-linked immunosorbent assay (ELISA) titration method for quantitation of the 70,000 Dalton glycoprotein (gp70) antigen of feline leukemia virus (FeLV) vaccines by the relative potency (RP) method. The RP of a Test Vaccine is determined by comparing the amount of gp70 antigen of a Test Vaccine to the gp70 antigen content of a Reference Preparation that has been directly or indirectly shown to be protective in a host animal immunogenicity trial.

## 2. Materials

### 2.1 Equipment/instrumentation

Equivalent equipment or instrumentation may be substituted for any brand name listed below.

2.1.1 Incubator 36° ± 2°C, 5% ± 1% CO<sub>2</sub>, high humidity (Model 3158, Forma Scientific Inc.)

2.1.2 Microplate reader (Model MRX, Dynex Technologies Inc.)

2.1.3 Microplate washer (Model EL404, Bio-Tek Instruments Inc.)

2.1.4 Micropipettors: 200- $\mu$ l and 500- $\mu$ l single channel, 50-200  $\mu$ l x 12-channel, and tips

2.1.5 RP Calculation Method: Use the current version of *SAM for Evaluation by the Relative Potency Method of In Vitro Enzyme Immunoassays Used In Testing of Veterinary Vaccines (SAM 318)*

2.1.6 Current version of the U.S. Department of Agriculture, Center for Veterinary Biologic's (CVB) *Relative Potency Calculation Software (RelPot)* [available from CVB]

Supplemental Assay Method for Quantitating the GP70 Antigen of Feline Leukemia  
in Virus Veterinary Vaccines

**2.2 Reagents/supplies**

Equivalent reagents or supplies may be substituted for any brand name listed below. All reagents and supplies must be sterile.

**2.2.1 0.01 M Phosphate buffered saline (PBS)**

**2.2.1.1** 1.33 g sodium phosphate, dibasic, anhydrous ( $\text{Na}_2\text{HPO}_4$ )

**2.2.1.2** 0.22 g sodium phosphate, monobasic, monohydrate ( $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ )

**2.2.1.3** 8.5 g sodium chloride ( $\text{NaCl}$ )

**2.2.1.4** Q.S. to 100 ml with distilled water (DI)

**2.2.1.5** Adjust pH to 7.2-7.6 with 0.1 N sodium hydroxide ( $\text{NaOH}$ ) or 1.0 N hydrochloric acid ( $\text{HCl}$ ).

**2.2.1.6** Sterilize by autoclaving at 15 psi, 121° 2° C for 35 ! 5 minutes.

**2.2.1.7** Store at 2°- 7° C.

**2.2.2 0.05 M Carbonate/Bicarbonate Coating Buffer, pH 9.6**

**2.2.2.1** 0.159 g sodium carbonate ( $\text{Na}_2\text{CO}_3$ )

**2.2.2.2** 0.293 g sodium bicarbonate ( $\text{NaHCO}_3$ )

**2.2.2.3** Q.S. to 100 ml with DI.

**2.2.2.4** Adjust pH to 9.6 with 1.0 N  $\text{HCl}$ .

**2.2.2.5** Store at 2°- 7° C; use within 1 week.

**2.2.3 Blotting**

**2.2.3.1** 1.5 g nonfat dry milk powder (*Flavorite* Instant Nonfat Dry Milk, extra grade, Preferred Products Inc.) [Brands and lots may vary in blocking ability. Determine appropriate percentage of dry milk for each batch.]

**2.2.3.2** 100 ml PBS

Supplemental Assay Method for Quantitating the GP70 Antigen of Feline Leukemia  
in Virus Veterinary Vaccines

- 2.2.3.3 Add 2 µl of Antifoam A.
- 2.2.3.4 Store at 2°- 7°C; use within 1 week.
- 2.2.4 Diluent Buffer
  - 2.2.4.1 100 ml Blotto
  - 2.2.4.2 1.0 ml Triton X-100
  - 2.2.4.3 Store at 2°- 7°C; use within 1 week.
- 2.2.5 Washing Buffer
  - 2.2.5.1 1000 ml of 0.01 M PBS
  - 2.2.5.2 1.0 ml Tween-20
  - 2.2.5.3 Store at 2°- 7°C.
- 2.2.6 Goat Anti-FeLV gp70 Polyclonal Antibody [available from CVB]
- 2.2.7 Anti-FeLV gp70 monoclonal antibody (MAb) [available from CVB]
- 2.2.8 Goat anti-mouse horseradish peroxidase conjugate (Goat Anti-mouse Conjugate)
- 2.2.9 (2,2'-azino-di-{3 ethyl-benzthiazaline sulfonate 6})(ABTS) peroxidase substrate solution (Substrate Solution)
  - 2.2.9.1 Solution A, ABTS
  - 2.2.9.2 Solution B, Hydrogen Peroxide
- 2.2.10 FeLV gp70 Positive Control [available from CVB]
- 2.2.11 Reference preparation: Each manufacturer provides a Reference Vaccine that has been directly or indirectly shown to be protective in a host animal immunogenicity trial. The reference preparation is the lot number identified in Part V of the Animal and Plant Health Inspection Service (APHIS) filed Outline of Production or special outline. All subsequent serials produced by the manufacturer must have an RP equal to or greater than the RP value contained in the APHIS filed Outline of Production.
- 2.2.12 Immulon II®, flat bottom, 96-well plate

**Supplemental Assay Method for Quantitating the GP70 Antigen of Feline Leukemia  
in Virus Veterinary Vaccines**

**2.2.13** Flat bottom, 96-well plate (transfer plate)

**2.2.14** Plate Sealer

**3. Preparation for the test**

**3.1 Personnel qualifications/training**

Personnel must have training and experience in the immunological basis of antigen capture ELISA assays, the principles of Optical Densitometry (OD), and computer software analysis.

**3.2 Preparation of equipment/instrumentation**

On the day of the reading, the ELISA reader must be turned on at least 30 minutes prior to determination of the OD. Dual wavelength settings, 405-nm test wavelength measured against a 490-nm reference wavelength, are used. The ELISA reader is zeroed on air prior to use.

**3.3 Preparation of reagents/control procedures**

**3.3.1** Test plate preparation. One to 5 days prior to test initiation, dilute the Goat Anti-gp70 Polyclonal Antibody, per the Center for Veterinary Biologics (CVB) Reagent Data Sheet supplied with the reagent, in Carbonate/Bicarbonate Coating Buffer.

**3.3.1.1** Pipette 100 µl/well of the Diluted Goat Anti-FeLV gp70 Polyclonal Antibody to all wells of a flat bottom, 96-well Immulon II® plate. This becomes the Test Plate.

**3.3.1.2** Cover the Test Plate with a Plate Sealer and incubate at 3 ! 2 days, at 2°- 7°C.

**3.3.2** Diluted gp70 Positive Control preparation. On the day of testing, dilute the gp70 Positive Control, per the CVB Reagent Data Sheet supplied with the reagent, in Diluent Buffer.

**3.3.3** Diluted Anti-gp70 MAb preparation. On the day of testing, dilute the Anti-gp70 MAb, per the CVB Reagent Data Sheet supplied with the reagent, in Blotto.

**Supplemental Assay Method for Quantitating the GP70 Antigen of Feline Leukemia  
in Virus Veterinary Vaccines**

**3.3.4** Diluted Goat Anti-mouse Conjugate. On the day of testing, dilute the Goat Anti-mouse Conjugate, per previously determined optimal dilution, in PBS. Optimal dilution results in an OD reading between 0.400 and 0.700 when incubated at 36° ± 2°C for 20 ± 10 minutes.

**3.3.5** Substrate Solution preparation. On the day of testing, just prior to substrate addition, mix equal volumes of ABTS Solution A and Hydrogen Peroxide Substrate Solution B per the manufacturer's instructions. The resulting Substrate Solution should remain clear and should be at room temperature at time of use.

**3.4 Preparation of the sample**

**3.4.1** Antigen Extraction (Optional). If the Test Vaccine contains adjuvant which interferes with antigen detection, the firm may specify the procedure for extraction of the antigen from the adjuvant. If extraction is a necessary step, the extraction procedure will be included in Part V of the APHIS filed Outline of Production. The CVB will extract antigen using the firm's protocol. If no protocol is stated in either the APHIS filed Outline of Production or special outline, the test will be conducted at the CVB without extraction. If the Reference Preparation is a product reference, both the Reference Preparation and Test Vaccine must be treated identically. If the Reference Preparation is a purified preparation, the extraction procedure is not required.

**3.4.2** All samples must be at room temperature before testing. The initial test of a Test Vaccine will be with a single vial (a single sample from 1 vial). Make twofold dilutions of the Reference Preparation and the Test Vaccine in Diluent Buffer in a flat bottom, 96-well plate which becomes the Transfer Plate.

**3.4.3** An initial dilution of the Reference Vaccine and/or Test Vaccine may be made. This dilution is determined by the firm to assure the 6 dilutions tested encompass the linear portion of the regression curve. The starting dilution for the Reference Vaccine and/or the Test Vaccine shall be stated in Part V of the APHIS filed Outline of Production or special outline. Unless stated otherwise, the diluent will be Diluent Buffer for the initial dilution.

**Supplemental Assay Method for Quantitating the GP70 Antigen of Feline Leukemia  
in Virus Veterinary Vaccines**

**3.4.3.1** Pipette 150 µl of Diluent Buffer to wells in rows C-G of the Transfer Plate with a 12-channel micropipettor (see **Appendix I**).

**3.4.3.2** Pipette 300 µl of the starting dilution of the Reference Preparation to 3 wells in row B of the Transfer Plate (see **Appendix I**).

**3.4.3.3** Pipette 300 µl of the starting dilution of the first Test Vaccine to 3 adjacent wells in row B of the Transfer Plate. An additional Test Vaccine may be tested into the next 3 adjacent wells.

**3.4.3.4** With a 12-channel micropipettor and the appropriate number of tips to correspond to the number of wells used in a row, mix row B (7 ! 2 fills) and transfer 150 µl to row C of the Transfer Plate. Replace tips, mix row C, and transfer 150 µl to row D.

**3.4.3.5** Continue as in **Section 3.4.3.4** for the remaining rows D-G of the Transfer Plate, transferring 150 µl from the previous to the next row.

**4. Performance of the test**

**4.1** On the day of testing, remove the Plate Sealer and pipette 200 µl of thoroughly mixed Blotto to each well of the Test Plate already containing Diluted Goat Anti-gp70 Polyclonal Antibody. Do not remove the Diluted Goat Anti-gp70 Polyclonal Antibody prior to adding the Blotto. Reseal plate and incubate at 2°- 7°C for 90 ! 30 minutes.



**Supplemental Assay Method for Quantitating the GP70 Antigen of Feline Leukemia  
in Virus Veterinary Vaccines**

**4.2** Decant Blot to from the Test Plate. Pipette 200-300  $\mu$ l of Washing Buffer into each well. Immediately decant Washing Buffer from the plate. Repeat for a total of 3 washes. At no time should wells dry between washes or incubations. An automatic microplate washer may be used.

**4.3** Transfer 100  $\mu$ l/well of each dilution in the Transfer Plate (starting in row G, most dilute, and ending in row B, least dilute) to appropriate rows of the Test Plate (see **Appendix I**). Tips need not be changed between rows when proceeding from most dilute to successively more concentrated dilutions.

**4.4** Pipette 100  $\mu$ l/well of Diluted gp70 Positive Control to wells 11-B, 11-C, and 11-D of the Test Plate.

**4.5** Pipette 100  $\mu$ l/well of Diluent Buffer to wells 11-E, 11-F, and 11-G of the Test Plate to serve as blanks.

**4.6** Seal the Test Plate with a Plate Sealer; incubate at 36°! 2°C for 60 ! 10 minutes.

**4.7** Wash the Test Plate as in **Section 4.2**.

**4.8** Pipette 100  $\mu$ l/well of Diluted Anti-gp70 MAb to all wells of the Test Plate.

**4.9** Seal the Test Plate with a Plate Sealer; incubate at 36°! 2°C for 60 ! 10 minutes.

**4.10** Wash the Test Plate as in **Section 4.2**.

**4.11** Pipette 100  $\mu$ l/well of Diluted Goat Anti-mouse. Conjugate to all wells of the Test Plate.

**4.12** Seal the Test Plate with a Plate Sealer; incubate at 36°! 2°C for 60 ! 10 minutes.

**4.13** Wash the Test Plate as in **Section 4.2**, then wash 2 times with PBS instead of Washing Buffer.

**4.14** Pipette 100  $\mu$ l/well of Substrate Solution to all wells of the Test Plate.

**4.15** Incubate the Test Plate at room temperature for 20 ! 10 minutes.

**Supplemental Assay Method for Quantitating the GP70 Antigen of Feline Leukemia  
in Virus Veterinary Vaccines**

**4.16** Read the Test Plate at 405-nm test wavelength against a 490-nm reference wavelength, when the Positive Control wells (11-B, C, D) read between 0.400 and 0.700 OD after the average blank reading is subtracted.

**4.17** The arithmetic mean of the blank wells is determined; this becomes the average blank reading. The average blank reading is subtracted from all readings before analysis of the data by *RelPot*.

**4.18** Evaluate results using *RelPot*.

**5. Interpretation of the test results**

**5.1** If the corrected OD of the Positive Control is not within the 0.400-0.700 OD range, the test is considered a **NO-TEST** and can be repeated without prejudice.

**5.2** All validity criteria in the current version of SAM 318 must be met for a valid test. An invalid test may be repeated. Testing may be repeated for **EQUIVOCAL** tests as defined in 9 CFR, Part 113.8(c)(4).

**5.3** For a given Test Vaccine to be **SATISFACTORY**, the RP value of at least 1 valid RP from the group of the highest scoring valid RP values has to be greater than or equal to the RP contained in an APHIS filed Outline of Production.

**5.4** For a Test Vaccine result less than the RP contained in an APHIS filed Outline of Production, the test may be repeated if the test meets 9 CFR, Part 113.8(c)(5) criteria.

**6. Report of test results**

Results are reported as the RP for the Test Vaccine. The highest RP of the top scores shall be considered the RP value for reporting purposes.

**7. References**

**7.1** Code of Federal Regulations, Title 9, Part 113.8, U.S. Government Printing Office, Washington, DC, 2004.

**Supplemental Assay Method for Quantitating the GP70 Antigen of Feline Leukemia  
in Virus Veterinary Vaccines**

**7.2** Shibley GP, Tanner JE, Hanna SA, United States  
Department of Agriculture licensing requirements for feline  
leukemia virus vaccines. *JAVMA*, (1991), Vol 199, No. 10,  
1402-1406.

**8. Summary of revisions**

This document was rewritten to clarify the practices currently in use at the Center for Veterinary Biologics and to provide additional detail. While no significant changes were made that impact the outcome of the test, the following changes were made to the document:

- The refrigeration temperatures have been changed from  $4^{\circ} \pm 2^{\circ}\text{C}$  to  $2^{\circ} - 7^{\circ}\text{C}$ . This reflects the parameters established and monitored by the Rees system.
- "Test Serial" has been changed to "Test Vaccine" throughout the document.
- "Reference and Reagent Sheet" has been changed to "Reagent Data Sheet" throughout the document.
- The footnotes have been deleted with any pertinent references now noted next to the individual items.

